Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Willemijntje Hoogerwerf

Gastroenterology St Augustine, FL Medical Doctor

NPI 1548348089 CMS profile 252168

100 Whetstone Pl, Suite 105, St Augustine, FL 32086

Open in the dashboard

General payments

$9,599

517 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Willemijntje Hoogerwerf of St Augustine, FL is reported in the CMS Open Payments database as having received $9,599 across 517 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,388 104
2024 General $1,727 82
2023 General $1,772 112
2022 General $1,485 91
2021 General $1,344 83
2020 General $269 16
2019 General $615 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Willemijntje Hoogerwerf
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Willemijntje Hoogerwerf were reported at $2,388. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Willemijntje Hoogerwerf Gastroenterology median Middle half National median
2019 $615 $417 $126–$1,100 $163
2020 $269 $224 $74–$624 $114
2021 $1,344 $352 $106–$1,054 $132
2022 $1,485 $448 $129–$1,270 $149
2023 $1,772 $533 $150–$1,390 $160
2024 $1,727 $605 $160–$1,606 $164
2025 $2,388 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,346 128 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,201 109 payments
  3. Janssen Biotech, Inc. $1,022 52 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $753 42 payments
  5. Genzyme Corporation $552 25 payments
  6. Madrigal Pharmaceuticals $513 18 payments
  7. Celgene Corporation $346 23 payments
  8. Regeneron Healthcare Solutions, Inc. $321 11 payments
  9. Pfizer Inc. $272 17 payments
  10. Medtronic, Inc. $218 2 payments
  11. Other $2,053 90 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,542 516 payments
  2. Education $57 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,163 107 payments
  2. STELARA $745 37 payments
  3. RINVOQ $693 35 payments
  4. SKYRIZI $586 26 payments
  5. LINZESS $580 43 payments
  6. DUPIXENT $552 25 payments
  7. CREON $525 36 payments
  8. TREMFYA $515 17 payments
  9. ENTYVIO $494 27 payments
  10. REZDIFFRA $447 14 payments
  11. Other $4,450 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,529

Median for Gastroenterology: 569

Drug cost

$1,020,658

Median for Gastroenterology: $104,976

Branded share of claims

29.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 25 $679,158
Humira(Cf) Pen Adalimumab Brand 14 $89,783
Zenpep Lipase/Protease/Amylase Brand 18 $87,146
Xifaxan Rifaximin Brand 30 $58,331
Creon Lipase/Protease/Amylase Brand 18 $20,810
Linzess Linaclotide Brand 16 $18,178
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 177 $11,237
Movantik Naloxegol Oxalate Brand 21 $11,068
Colestipol Hcl Generic 101 $6,330
Dexlansoprazole Dr Dexlansoprazole Brand 12 $6,226

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$354,634

Of which drugs: $182,543

Medicare patients

855

Average age 74

Services billed

13,864

627 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 36%
Diabetes 25%
Depression 24%
Chronic kidney disease 23%
Osteoporosis 22%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 12 6,300 $108,305
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 15 2,670 $62,788
Infusion, normal saline solution, 250 cc J7050 Office 35 86 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $259
$259 — —
SKYRIZI
  • AbbVie, Inc. $242
$242 — —
DUPIXENT
  • GENZYME CORPORATION $100
  • Regeneron Healthcare Solutions, Inc. $64
$163 — —
RINVOQ
  • AbbVie, Inc. $144
$144 — —
STELARA
  • Janssen Biotech, Inc. $133
$133 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

517 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record